Lipocine, Inc.
(NASDAQ : LPCN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc 1.42%4.871.6%$108.14m
VRXValeant Pharmaceuticals International, Inc. 6.91%15.6314.1%$91.97m
PRGOPerrigo Co. Plc -0.40%47.386.8%$86.20m
JAZZJazz Pharmaceuticals Plc 0.75%106.562.3%$84.50m
CTLTCatalent, Inc. 2.92%53.922.2%$77.02m
ICLRICON plc 2.16%148.204.2%$74.84m
HZNPHorizon Therapeutics Plc -0.89%31.686.5%$72.12m
UTHRUnited Therapeutics Corp. -0.61%95.1814.3%$71.26m
AXSMAxsome Therapeutics, Inc. 0.21%53.661.9%$65.33m
GWPHGW Pharmaceuticals Plc 4.18%90.206.2%$57.69m
ICPTIntercept Pharmaceuticals, Inc. 3.72%65.1916.8%$43.62m
SAGESAGE Therapeutics, Inc. 5.76%30.018.6%$42.17m
PBHPrestige Consumer Healthcare, Inc. 1.17%39.634.0%$36.09m
PCRXPacira Biosciences, Inc. 2.78%32.8910.4%$31.04m
MYOKMyoKardia, Inc. 0.42%48.252.1%$26.87m

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.